Markers of Severity (CD177,S100A8 &S100A12) in Sever Acute Respiratory Syndrome Coronavirus 2(SARS-COV-2) Patients

Study Overview
=================
Brief Summary
-----------------
Patients infected with covid-19 have a series of clinical manifestations, including fever, cough, myalgia or fatigue, dyspnea, even acute respiratory distress syndrome (ARDS), acute cardiac injury and secondary infection, and a lot of sever patients had to been admitted to the intensive care unit (ICU) One of the hallmark of COVID 19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. besides the positive viral nucleic acid analysis and the representative pulmonary CT findings (bilateral distribution of patchy shadows and ground glass opacity), most individual patients showed the changes in several immunological and biological markers . CD177 which is one of the most clinically important neutrophil alloantigen because: i) it is a neutrophil-specific marker representative of neutrophil activation, ii) it was the most highly differentiated expressed gene in patients, and iii) the protein can be measured in the serum, making its use as a marker clinically applicable. It is expressed on neutrophils, neutrophilic metamyelocytes, and myelocytes . Given the contribution of the neutrophil activation pathway in the clustering of COVID-19 patients, neutrophil-activation features that could act as possible reliable markers of disease evolution.

Official Title
-----------------
Markers of Severity in Covid 19 Patients

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Diagnostic Test: real time PCR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COVID 19 hospitalized patients (diagnosed by RT-PCR) Exclusion Criteria: Age below 18 years and above 80.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: control group<br>Healthy control group | Diagnostic Test: real time PCR<br>* real time PCR<br>|
| Active Comparator: ICU COVID 19 patients<br>ICU COVID 19 patients | Diagnostic Test: real time PCR<br>* real time PCR<br>|
| Active Comparator: non-ICU covid 19 patients<br>non-ICU covid 19 patients | Diagnostic Test: real time PCR<br>* real time PCR<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Markers of severity(CD177) in Sever respiratory syndrome coronavirus 2 (SARS-COV-2) patients | - Measuring gene expression for CD 177 by RT-PCR and also by ELISA. Measuring gene expression for CD 177 by RT-PCR and also by ELISA. | one year | 
| Markers of severity(S100A8&S100A12) in Sever respiratory syndrome coronavirus 2 (SARS-COV-2) patients | Measuring level of S100A8 and S100A12 by ELISA. | one year |